Интал

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Интал

Understanding Intal

Intal is a non-steroidal medication used as a long-term preventive measure in the management of bronchial asthma and other allergic conditions. Its active ingredient is sodium cromoglicate, a substance classified as a mast cell stabilizer. Unlike rescue inhalers, this medication is designed to be used regularly to maintain respiratory stability rather than to provide immediate relief during an acute attack.

Mechanism of Action

The primary function of the active substance is to prevent the release of inflammatory mediators, such as histamine and leukotrienes, from specialized immune cells known as mast cells. These mediators are typically released when a person with sensitive airways is exposed to specific triggers, such as allergens, cold air, or physical exertion. By stabilizing the membranes of these cells, the medication helps reduce the underlying inflammation and hyperreactivity of the bronchial tubes.

Therapeutic Role

Intal is utilized in various clinical scenarios involving allergic inflammation:

  • Bronchial Asthma: It is used as a maintenance therapy to reduce the frequency and severity of asthma symptoms. When used consistently, it may help decrease the overall sensitivity of the airways.
  • Exercise-Induced Bronchospasm: It can be used to prevent the narrowing of the airways that occurs specifically during or after physical activity.
  • Allergic Rhinitis: In certain formulations, it helps manage the inflammatory response in the nasal passages caused by seasonal or perennial allergens.

Clinical Characteristics

Because it does not possess bronchodilating or anti-inflammatory properties similar to corticosteroids, its effects are prophylactic. It acts as a protective shield for the airways, requiring several weeks of consistent use before the full therapeutic benefits are typically observed. It is often integrated into a broader management plan for patients who require a non-hormonal approach to preventing allergic reactions and maintaining long-term respiratory health.

What side effects are possible with Интал?

Possible Side Effects and Safety Information

The safety profile for Sodium Cromoglycate (Интал) is characterized by a low incidence of systemic adverse reactions, with the most frequently observed effects being localized and administration-related, as documented in regulatory labeling.

Adverse Reactions Classified by Frequency

Official prescribing information classifies most systemic effects as rare events. The more commonly reported effects are typically localized:

  • Common/Expected Reactions: These are often associated with the inhalation process, including coughing, mild wheezing, and irritation or dryness of the throat. Nasal congestion and sneezing may also be noted.
  • Rare Systemic Reactions: Reactions are generally reported in categories of low incidence (e.g., less than 1 in 10,000 patients). These can involve the gastrointestinal system (nausea, stomach ache) and the nervous system (dizziness, drowsiness), as classified in System-Organ-Classes (SOC).

Serious Adverse Reactions

Regulators document rare but clinically significant adverse reactions, primarily related to immune system disorders and hypersensitivity. These include anaphylactic reactions and severe bronchospasm, which may occur following inhalation and could necessitate discontinuation of therapy. Rare systemic events like pulmonary infiltrates with eosinophilia and certain forms of vasculitis have also been reported.

Population-Specific Safety Considerations

Safety constraints are defined for specific patient groups and usage contexts:

  • Contraindications: The medicine is formally contraindicated in patients with a known hypersensitivity to the active ingredient, Sodium Cromoglycate.
  • Pediatrics: Safety and effectiveness for the inhalation solution have not been established in children below the age of 2 years.
  • Organ Function: In patients with decreased renal or hepatic function, regulatory guidance suggests that dosage consideration should be given due to the routes of excretion.
  • Aerosol Restrictions: The propellants used in the aerosol inhaler may potentially worsen pre-existing heart conditions or irregular heartbeat, and the medicine is not indicated for the treatment of acute asthma attacks.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose profile for Sodium Cromoglycate (Intal), based strictly on government regulatory documents.


Documented Overdose Profile

Aspect Regulatory Statement
Systemic Toxicity Risk The risk of acute systemic toxicity following overdose of the inhalation product is considered low due to the drug's poor absorption from the respiratory and gastrointestinal tracts.
Clinical Manifestations Official labeling does not specify unique, definitive clinical signs or symptoms resulting directly from acute overdose.
Life-Threatening Outcomes Acute over-inhalation is generally not anticipated to lead to serious adverse clinical consequences.

Mandated Emergency Actions

Action Required Official Regulatory Instruction
Emergency Help-Seeking Patients must seek medical attention immediately in the event of a suspected or confirmed overdose.
Antidote Availability It is formally documented that no specific antidote is known for Sodium Cromoglycate overdose.
Management Approach Overdose management is limited to symptomatic and supportive treatment.

Upon confirmed overdose, the medication must be discontinued. Due to the low anticipated risk of severe outcomes and the absence of a known antidote, regulatory guidance focuses entirely on ensuring the patient receives appropriate supportive care and observation. This prescribed action ensures that any non-specific symptoms are managed effectively following excessive exposure.

Therapeutic Uses of Интал

Интал is applied as a preventative treatment for chronic allergic and asthmatic conditions. It is considered relevant when additional symptomatic support is needed to assist with maintaining functional stability and ease overall discomfort.

This medication is considered relevant for managing conditions characterized by periods of heightened symptoms that create noticeable physiological strain, including mild to moderate chronic asthma, Exercise-Induced Bronchoconstriction (EIB), allergic rhinitis (hay fever), and various forms of allergic conjunctivitis. It is helpful in situations where multiple symptoms occur together and where supportive management may be appropriate.

“It is considered relevant when short-term symptomatic assistance is appropriate, as it may assist with maintaining a sense of stability when symptoms are more noticeable.”

This use provides supportive relief that helps ease the overall symptom load related to recurrent wheezing, chest tightness, acute breathing reactions, eye itching, redness, and nasal irritation. It is applied in scenarios where additional management of discomfort is required, and may help contribute to improved day-to-day comfort during symptomatic periods.

Therapeutic Focus: Management of Recurrent Wheezing

Regulatory References

  1. NIH MedlinePlus

Eligibility and Restrictions for Use

Who Can and Cannot Use Интал? — Official Regulatory Information

Eligibility to use Интал (Sodium Cromoglycate) is strictly defined by regulatory documents based on patient population and medical status.

Category Eligibility Rule
Contraindicated Populations Patients with known hypersensitivity to Sodium Cromoglycate or any other component of the specific formulation must not use the medicine.
Use Case Restriction It is not indicated for the treatment of acute asthma attacks (Status Asthmaticus). The drug is exclusively for prophylactic management.

Eligibility is further determined by age. Use of the Inhalation Solution is generally approved for adults and children 2 years of age and older. Safety and effectiveness in pediatric patients below 2 years of age have not been established. The minimum approved age for the Inhalation Aerosol is typically 5 years of age.

For physiological states, the FDA categorizes the drug as Pregnancy Category B; it should be used only if clearly needed. Caution is advised for use in nursing mothers as it is not known whether the drug is excreted in human milk. Patients with severe renal or hepatic impairment may require consideration for dosage reduction, reflecting caution regarding the drug's excretion pathways.

What should I know about interactions with other medicines?

The official regulatory profile for Sodium Cromoglycate inhalation establishes a minimal risk for systemic drug interactions. This is primarily determined by the drug’s pharmacokinetic characteristics: only a small percentage (approximately 8%) of the inhaled dose is absorbed into the bloodstream, and this absorbed portion is rapidly excreted unchanged in the urine and bile. Because the drug is not metabolized by the liver’s enzyme systems, such as the Cytochrome P450 pathway, official documentation lists no known exposure-altering interactions, nor does it classify any medicines as formally contraindicated due to a metabolic mechanism.

The drug's official interaction documentation confirms its pattern of permitted co-administration with other treatments for respiratory management. Specifically, regulatory labels indicate that the product may be used concurrently with beta-agonist bronchodilators and inhaled corticosteroids without requiring a modification to the typical administration schedule.

A procedural constraint on administration is noted: the safety and physical stability of mixing the Sodium Cromoglycate solution with other medicinal products directly in the nebulizer cup have not been established by regulatory review. Furthermore, no specific interactions with food, alcohol, or herbal products are documented in the official prescribing information. Consideration for dosage is mentioned in specific populations, with caution noted in cases of severe renal or hepatic impairment due to the drug's primary routes of excretion.

Mechanism of Action

How Интал Works

The mechanism of action for Интал (Cromolyn Sodium) centers on the targeted modulation of cellular inflammatory responses through mast cell stabilization. The drug is applied in biological systems where the release of inflammatory mediators is activated.

Mast Cell Membrane Stabilization

Интал acts by inhibiting the influx of calcium ions (Ca^2+) into mast cells, which is the critical initial step required for cellular degranulation. By preventing this signaling sequence, the drug restricts the magnitude of mediator release, including histamine and leukotrienes.

Modulation of Cellular Activation Threshold

Интал engages mechanisms that regulate overactive cellular processes associated with immediate immune reactions. By blocking the rapid degranulation cascade, the drug alters the cellular signaling kinetics within targeted pathways. This modifies the threshold of cellular activation in target tissues, resulting in an altered physiological response pattern rather than an explosive localized reaction.

Dosage and Administration Information

How to Use Intal (Cromolyn Sodium) — Administration Guidelines

This section outlines the instructions for the proper administration of Intal (cromolyn sodium). All instructions are strictly procedural and should be followed as directed by a healthcare professional.


Administration Scope and Dosage

Category Instructions
Route of Administration Inhalation (Metered-Dose Inhaler or Nebulizer Solution) or Oral (Solution).
Standard Dosing Schedule Four times daily (QID) at regular, equally spaced intervals.
Inhalation Dose Two metered inhalations four times daily, or the contents of one 20 mg Nebulizer Solution vial four times daily.
Oral Solution Dose Adults/Adolescents (13 years and older): Two 100 mg ampules four times daily. Children (2–12 years): One 100 mg ampule four times daily.

Procedural and Timing Requirements

Administration Timing:

  • Inhalation: Maintenance doses must be taken on a continuous, scheduled basis. For exercise-induced use, the drug must be administered within 10 to 15 minutes (not more than 60 minutes) before exposure to the precipitating factor.
  • Oral Solution: Must be taken one-half hour before meals and again at bedtime.

Preparation Requirements (Oral Solution):

  • The ampule contents must be diluted by squeezing the liquid into a glass of water, stirring, and drinking the entire amount.
  • Do not mix with milk, fruit juice, or food.

Age-Group Rules:

  • The Metered-Dose Inhaler is not recommended for children younger than 5 years.
  • The Nebulizer Solution is approved for patients 2 years of age and over.

Missed Doses: If a dose is missed, continue with the regular schedule. Do not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Интал (Sodium Cromoglycate)

The research landscape for Chronic Asthma consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews exploring changes in symptoms over time. Studies focused historically on individuals with mild to moderate asthma. Research has examined outcomes related to physiological strain, specifically monitoring objective lung function metrics (such as FEV1 and PEF), and tracking outcomes related to daily functioning, such as the patient-reported frequency of required rescue inhaler use. Data related to symptom outcomes have been mixed across various systematic reviews, and the overall evidence quality varies across studies. The evidence is generally categorized as Low to Moderate certainty.

Evidence for Exercise-Induced Bronchoconstriction (EIB) relies on acute, short-term crossover studies where research examined immediate physiological changes shortly before a standardized exercise challenge. The research structure is generally categorized as High for describing the acute physiological response in this setting. For Allergic Rhinitis and Conjunctivitis, the evidence base relies on RCTs exploring patient-reported outcomes for perceived discomfort, like itching and tearing. Studies reported patterns where continuous use was related to the full physiological pattern after approximately one to two weeks, and the certainty level for these indications is generally categorized as Moderate.

Most research utilized follow-up durations limited to a few weeks or months. Studies exploring the durability of the observed physiological patterns or symptom outcomes over multiple years of use are not fully established by large-scale, extended-duration RCTs. While the evidence base includes extensive study of children with chronic asthma, making this age group a well-characterized population, data for other groups remain insufficient within the controlled trial setting. A consistent finding across reviews is that comparative evidence is lacking for certain long-term outcomes when assessed directly against control treatments.

Key Studies & References

  1. MedlinePlus Drug Information: Cromolyn Inhalation

Frequently Asked Questions (FAQ)

Common questions about Интал (FAQ)


Q: How long does it usually take to feel the effects of Интал after starting it?

According to official clinical documentation for the inhalation product, if improvement in symptoms is going to occur, it typically begins within the first four weeks of continuous, regular administration. Because this medicine is a preventative agent, it requires consistent use to reach its full effect and help decrease symptoms over time.


Q: What are the most commonly reported mild side effects of Интал?

The most commonly reported effects associated with Интал are typically localized and mild. Official regulatory documents list coughing, nausea, and irritation or dryness of the throat as common or expected side effects after use.


Q: Is it normal to feel a slight throat irritation after using Интал?

Yes, regulatory documents list throat irritation or dryness as a common or expected reaction associated with the inhalation process. This is a localized effect that may occur when using an inhaler.


Q: Can I stop taking Интал once my symptoms improve?

Official guidance advises against abruptly stopping the medication without consulting a healthcare provider. Because the medicine works preventatively, abruptly discontinuing it may be associated with a return or worsening of symptoms.


Q: Are there any official reports about Интал's safety for breastfeeding mothers?

Official information advises caution for use in nursing mothers. This is because it is currently not known whether the drug is excreted into human breast milk.


Q: Can I use Интал if I have liver or kidney problems?

Caution is advised for individuals with severe renal (kidney) or hepatic (liver) impairment. Because the drug is primarily excreted through these organs, official guidance suggests that dosage consideration may be needed for these patients.


Q: Does using Интал prevent future severe episodes?

Интал is classified as a prophylactic agent intended to prevent inflammation by stabilizing mast cells and is used for maintenance. However, it is not indicated for the treatment of acute, severe episodes (such as Status Asthmaticus) and is not intended to be used for the immediate management of severe events.


Q: What is Интал used for besides the main conditions?

In addition to its use for respiratory conditions, the oral solution formulation of cromolyn sodium is officially approved for the treatment of certain gastrointestinal symptoms associated with a rare condition called mastocytosis.


Q: Do you feel or taste anything when using the Интал inhaler?

Official documents note that an unpleasant taste may be a reported effect associated with the use of the medicine, particularly with the oral solution formulation.


Q: Can Интал be used by children, and is the dose different?

The minimum approved age for the inhalation solution is generally 2 years of age. For the oral solution, official dosage schedules are designated as different for children aged 2–12 years compared to adolescents and adults.


Q: Why is Интал often used for prevention instead of immediate relief?

The drug is officially classified as a mast cell stabilizer, which means its mechanism is to prevent the release of inflammatory chemicals before they cause symptoms. Because of this preventative action, it has no bronchodilator activity and is not effective for relieving acute symptoms that have already started.


Q: Is there a generic version of Интал available?

Yes, the active ingredient, cromolyn sodium, is available from multiple manufacturers under generic labeling. Regulatory product listings confirm the availability of generic versions of the drug.


Q: Are there any common foods or drinks that interact with Интал?

Official regulatory labels state that no specific interactions with food, alcohol, or herbal products are documented for the inhalation product. For the oral solution, there are preparation requirements, such as the solution should not be mixed with milk or fruit juice.


Q: Can Интал cause changes in sleep patterns?

Official documentation lists insomnia (difficulty sleeping) as one of the reported side effects in the nervous/psychiatric system category. If this occurs, it is generally considered a rare systemic event.


Q: Is Интал safe to use if I am also taking vitamins or herbal supplements?

Official guidance recommends that a patient discusses the use of any prescription, over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and other supplements with a healthcare professional. This approach is advised as part of the overall patient guidance.


Q: What is the difference between Интал and a quick-relief inhaler?

Интал is a mast cell stabilizer used for continuous, preventative treatment and has no bronchodilator activity. In contrast, a quick-relief inhaler is a type of bronchodilator used to reverse acute symptoms by opening the airways immediately, but it does not provide long-term preventative control.


Q: Does Интал lose its effectiveness over time?

The drug is intended for a continuous program of medication to maintain predictable airway function over a long period. Official studies do not suggest that the medication develops tolerance or that its efficacy is reduced over time with continued use.


Q: Can I use Интал during allergy season only?

Official regulatory labeling indicates that the medicine is intended to be taken on a continuous, scheduled basis for sustained, long-term, and preventative management. The continuous use schedule is based on official documents, and any change in schedule is typically discussed with a healthcare provider.


Q: Does Интал interact with common cold or flu medicines?

Official guidance recommends discussing the use of any prescription or non-prescription (over-the-counter [OTC]) medicine with a healthcare professional before use. This is standard guidance for all non-prescription medications.


Q: What is the risk of developing a serious side effect from Интал?

Regulatory documents classify serious adverse reactions, such as severe bronchospasm or anaphylaxis, as rare events. These events are typically reported in categories of very low incidence, for example, less than 1 in 10,000 patients.


Q: Can I take Интал if I have high blood pressure?

Official warnings note that the propellants used in the aerosol inhaler formulation may potentially worsen pre-existing heart conditions or irregular heartbeat. Official documentation advises that existing cardiac conditions are typically discussed with a healthcare professional.


Q: Does Интал have any known interactions with alcohol?

Official regulatory labels state that no specific interactions with alcohol are documented for the inhalation product. However, any questions regarding alcohol consumption are typically directed to a healthcare professional.


Q: Can using Интал affect the results of blood tests?

Regulatory documents list rare, postmarketing reports of changes to certain laboratory values, including some related to hematologic (blood) and hepatic (liver function) outcomes. These are typically monitored via blood tests.


Q: What types of allergies is Интал usually used to prevent?

The drug is officially indicated for the preventative treatment of allergy symptoms, most notably those associated with bronchial asthma. It is also indicated for specific allergic conditions such as allergic rhinitis (nasal) and allergic conjunctivitis (eye).


Q: How should I clean the Интал device?

Official administration instructions advise that the device, such as the nebulizer or aerosol actuator, must be cleaned regularly. Users should follow the manufacturer's directions carefully for cleaning after each use.


Q: What are the signs that Интал is actually working?

Improvement usually occurs within the first four weeks of use. Official documents state this is demonstrated by a decrease in the severity of clinical symptoms or a reduced need for concomitant therapy, such as the frequency of rescue inhaler use.


Q: Does the effectiveness of Интал change based on the way it's inhaled?

Official instructions emphasize the importance of proper inhalation technique, such as pressing the canister at the exact time of breathing in, for the medication to work as intended. Proper use is considered essential for effective delivery.


Q: Why do official documents mention mast cells when describing Интал?

Official documents classify the drug as a Mast Cell Stabilizer because its primary action is to prevent the release of chemicals like histamine from mast cells. Since these cells are key triggers in the body's inflammatory and allergic responses, they are central to the drug's purpose.


Q: Can Интал be used with a spacer device?

The administration instructions for some inhalation formulations may provide specific information regarding the use of a spacer device. This is generally permitted and can assist with the proper delivery of the inhaled medication.


Q: What is the shelf life of the Интал product?

Official labeling requires the expiration date to be prominently printed on the product packaging. The medication must be stored according to the specified conditions, such as temperature and light protection, until that printed date.


Q: Can I take Интал if I have asthma but no allergies?

Yes, the inhalation medicine is officially indicated for the prophylactic (preventative) treatment of bronchial asthma. This indication is for patients whose symptoms are frequent enough to require a continuous medication program, regardless of the underlying cause.

How should Интал be stored and disposed of?

How to Store and Dispose of Intal (Cromolyn Sodium) — Official Requirements

Intal (Cromolyn Sodium) must be stored strictly according to the labeled requirements to maintain its stability and effectiveness.

Storage & Stability Requirements

  • Temperature: Store at Controlled Room Temperature, typically between 15 C to 30 C (59 F to 86 F), or below 25 C depending on the product form.
  • Protection: Protect from light by retaining the product in its original foil pouch or carton until the moment of use. Keep the medication from freezing.
  • Condition: Do not use the nebulizer solution if it appears discolored, cloudy, or contains a precipitate.
  • After Opening: Nebulizer solution ampoules are for single use; discard any unused solution immediately after opening.
  • Child Safety: Keep this and all medications out of the sight and reach of children.

Disposal Requirements

  • All unused or expired medication must be disposed of properly according to local waste regulations. Do not flush any unused medicine down the toilet or pour it into a drain unless instructed to do so by a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Интал found in:

A-Z Index: